Somatostatin Receptors 2 and 5 Are the Major Somatostatin Receptors in Insulinomas: An in Vivo and in Vitro Study

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5353-5360

  Bertherat, J ^a,c   Tenenbaum, F ^a   Perlemoine, K ^c   Videau, C ^b   Alberini, J L ^a   Richard, B ^a   Dousset, B ^a   Bertagna, X ^a,c   Epelbaum, J ^b  

^a Cochin Hospital ^*  (France)

^b IFR 77 Broca Sainte Anne   (France)

^c INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIM 23244; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; IODINE DERIVATIVE; L 779976; L 796778; L 797591; L 803087; L 817818; RECEPTOR SUBTYPE; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR AGONIST; SOMATOSTATIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INSULINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCINTIGRAPHY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AUTORADIOGRAPHY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULINOMA; IODINE RADIOISOTOPES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOMATOSTATIN;

EID: 0344394952     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021895     Document Type: Article

References (52)

1. Reisine T, Bell GI 1995 Molecular biology of somatostatin receptors. Endocr Rev 16:427-442
2. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
3. Lamberts SW, Krenning EP, Reubi JC 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482
4. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
5. Service FJ, McMahon MM, O'Brien PC, Ballard DJ 1991 Functioning insulinoma - incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66:711-719
6. Perry RR, Vinik AI 1995 Diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab 80:2273-2278
7. Laron Z 1990 Somatostatin analogues in the management of benign insulinomas. Isr J Med Sci 26:1-2
8. Arnold R, Simon B, Wied M 2000 Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62:84-91
9. Glaser B, Rosler A, Halperin Y 1990 Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995. Isr J Med Sci 26: 16-19
10. Timmer R, Koningsberger JC, Erkelens DW, Thijssen JH, Lips CJ, Koppeschaar HP 1991 No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma. Neth J Med 38:199-203
11. Bertherat J, Turpin G, Rauch C, Li JY, Epelbaum J, Sassolas G, Schaison G 1994 Presence of somatostatin receptors negatively coupled to adenylate cyclase in ectopic growth hormone-releasing hormone-and α-subunit- secreting tumors from acromegalic patients responsive to octreotide. J Clin Endocrinol Metab 79:1457-1464
12. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH 1989 Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug? Neth J Med 35:86-94
13. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA 1989 Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinol (Copenh) 121: 34-40
14. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM 1998 Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737-740
15. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM 2000 Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117
16. Moldovan S, Atiya A, Adrian TE, Kleinman RM, Lloyd K, Olthoff K, Imagawa D, Shevlin L, Coy D, Walsh J, et al 1995 Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J Surg Res 59:85-90
17. Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J 1998 Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab 83:3746-3749
18. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48:77-85
19. Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG, Eizirik DL 1999 Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 57: 1159-1164
20. Reubi JC 1992 Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med 65:493-503; discussion 531-536
21. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321-1325
22. Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M, Lewin MJ 1997 Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 27:639-644
23. John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherubl H, Boese-Landgraf J, Neuhaus P, Ziske C, Molling K, Riecken EO, Reubi JC, Wiedenmann B 1996 Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38:33-39
24. Reubi JC, Schaer JC, Waser B, Mengod G 1994 Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455-3459
25. Moyse E, Beaudet A, Bertherat J, Epelbaum J 1992 Light microscopic radioautographic localization of somatostatin binding sites in the brainstem of the rat. J Chem Neuroanat 5:75-84
26. Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J 1992 Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 75:540-546
27. Perez J, Viollet C, Doublier S, Videau C, Epelbaum J, Baud L 2003 Somatostatin binds to murine macrophages through two distinct subsets of receptors. J Neuroimmunol 138:38-44
28. Bertherat J, Slama A, Kordon C, Videau C, Epelbaum J 1991 Characterization of pericellular [125I]Tyr0 DTrp8 somatostatin binding sites in the rat arcuate nucleus by a newly developed method: quantitative high-resolution light microscopic radioautography. Neuroscience 41:571-579
29. Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J 1993 Somatostatin receptors, adenyla te cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab 77:1577-1583
30. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461-475
31. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E, Patel YC 2002 Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 99:3294-3299
32. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288:154-157
33. Perez J, Rigo M, Kaupmann K, Bruns C, Yasuda K, Bell GI, Lubbert H, Hoyer D 1994 Localization of somatostatin (SRIF) SSTR-1, SSTR-2 and SSTR-3 receptor mRNA in rat brain by in situ hybridization. Naunyn Schmiedebergs Arch Pharmacol 349:145-160
34. Helboe L, Stidsen CE, Moller M 1998 Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst1 in the somatostatinergic parvocellular neuronal system of the rat hypothalamus. J Neurosci 18:4938-4945
35. Kulaksiz H, Eissele R, Rössler D, Schulz S, Höllt V, Cetin Y, Arnold R 2002 Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumors with subtype specific antibodies. Gut 50:52-60
36. Hannon J, Nunn C, Stolz B, Bruns C, Weckbecker G, Troxler T, Hurth K, Hoyer D 2002 Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci 18:15-27
37. Proye C, Malvaux P, Pattou F, Filoche B, Godchaux JM, Maunoury V, Palazzo L, Huglo D, Lefebvre J, Paris JC 1998 Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 124:1134-1143
38. Zimmer T, Stolzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B 1996 Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 39:562-568
39. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM 1998 Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 91:295-301
40. Jamar F, Fiasse R, Leners N, Pauwels S 1995 Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 36: 542-549
41. Meko JB, Doherty GM, Siegel BA, Norton JA 1996 Evaluation of somatostatin-receptor scintigraphy for detecting neuroendocrine tumors. Surgery 120: 975-983
42. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38:853-858
43. Cadiot G, Bonnaud G, Lebtahi R, Sarda L, Ruszniewski P, Le Guludec D, Mignon M 1997 Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gut 41:107-114
44. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT 1996 Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125:26-34
45. Schillaci O, Massa R, Scopinaro F 2000111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 41: 459-462
46. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S 1997 Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 100:2386-2392
47. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C 1996 Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 56: 1823-1827
48. Reubi JC, Waser B, Schaer JC, Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-846
49. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D, Plouin PF 1995 Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80:1837-1844
50. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86:3809-3814
51. Torrisani J, Bouisson M, Puente E, Capella G, Laurent-Puig P, Berger A, Vaysse N, Susini C, Buscail L 2001 Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology 120:200-209
52. Puente E, Saint-Laurent N, Torrisani J, Furet C, Schally AV, Vaysse N, Buscail L, Susini C 2001 Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-β. Involvement of Smad4. J Biol Chem 276:13461-13468